INX-315 is an oral, investigational selective cyclin-dependent kinase 2 (CDK2) inhibitor. The designation was based on preclinical data as well as interim data from the ongoing phase 1/2 INX-315 ...

Following the COVID-19 pandemic, mRNA-based vaccines have been shown to provide rapid and precise immune responses, however, this technology has much wider applications. Many leading pharma and ...

The US regulator has placed oral BTK inhibitor orelabrutinib on partial clinical hold, meaning new patients cannot be enrolled into clinical trials and patients treated with the drug for 70 days ...

H5N1 is a subtype of the Influenza A virus, named after two surface proteins: hemagglutinin (H) and neuraminidase (N). While there are several subtypes (such as H1N1 or H3N2), H5N1 is particularly ...

3Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama. 7O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama. Search for ...

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...

Notice: Given the ongoing transition to trivalent influenza vaccines, the availability of various influenza vaccine preparations in Canada is evolving and may change by fall 2025. Information about ...